SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-008803
Filing Date
2017-11-13
Accepted
2017-11-13 09:04:06
Documents
66
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20170930x10q.htm 10-Q 1365209
2 EX-31.1 gemp-20170930ex31159e5c2.htm EX-31.1 17582
3 EX-31.2 gemp-20170930ex312492067.htm EX-31.2 17672
4 EX-32.1 gemp-20170930ex321432012.htm EX-32.1 12036
  Complete submission text file 0001558370-17-008803.txt   5157528

Data Files

Seq Description Document Type Size
5 EX-101.INS gemp-20170930.xml EX-101.INS 814125
6 EX-101.SCH gemp-20170930.xsd EX-101.SCH 51184
7 EX-101.CAL gemp-20170930_cal.xml EX-101.CAL 30047
8 EX-101.DEF gemp-20170930_def.xml EX-101.DEF 214841
9 EX-101.LAB gemp-20170930_lab.xml EX-101.LAB 442402
10 EX-101.PRE gemp-20170930_pre.xml EX-101.PRE 349267
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 171193459
SIC: 2834 Pharmaceutical Preparations